Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Harvard Catalyst offices will be closed for winter recess December 22 - January 1.
Keywords
Last Name
Institution

profileSamia Mora, M.D.

TitleAssociate Professor of Medicine
InstitutionBrigham and Women's Hospital
DepartmentMedicine
AddressBrigham and Women
Prevntive Medicine - 3rd Fl
900 Commonwealth Ave
Boston MA 02215
Phone617/278-0783
Fax617/264-9194
vCardDownload vCard (login for email)
Profile Picture

Collapse Biography 
Collapse awards and honors
1992Harvard Foundation Award, Harvard University
1992Harvard University Stride Rite Postgraduate Fellowship
2003Helen B. Taussig Award for Postdoctoral Investigation, Johns Hopkins School of Medicine
2003American College of Cardiology Foundation Merck Fellowship for Clinical Investigation
2005Sandra A. Daugherty Foundation Cardiovascular Epidemiology Award
2007Lerner Research Young Investigator Award, Cardiovascular Division, Brigham and Women's Hospital
2011Johns Hopkins Fellows' Distinguished Speaker Visiting Professor
2011Circulation Editors' Choices, Groundbreaking Studies in the Practice of Cardiovascular Medicine
2015Chair's Research Award, Department of Medicine, Brigham and Women's Hospital
2015Joseph and Grace DeStevens Lecture, Northwestern University Feinberg School of Medicine
2017Jan J. Kellerman Memorial Award, International Academy of Cardiology

Collapse Mentoring 
Collapse completed student projects
A National Interactive Web-Based Physical Activity Intervention in Women: Evaluation of Choose to Move 2006-2007
Summer, 06/29/09 - 08/14/09
Angina with “Normal” Coronary Arteries (Cardiac Syndrome X): A Benign Prognosis?
Summer, 06/11/07 - 08/13/07

Collapse Research 
Collapse research activities and funding
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
R01HL134811     (MORA, SAMIA)Aug 15, 2017 - May 31, 2021
NIH/NHLBI
Reducing Inflammation for the Prevention of CVD: A Focus on Eicosanoid Pathways
Role: Principal Investigator

R01HL117861     (MORA, SAMIA)Jul 22, 2013 - Jun 30, 2017
NIH/NHLBI
HDL Heterogeneity and Function, Statin Therapy, and CVD Outcomes
Role: Principal Investigator

K08HL094375     (MORA, SAMIA)Jan 15, 2009 - Jun 30, 2013
NIH/NHLBI
Novel Lipoproteins, Cardiometabolic Risk, and Statin Therapy
Role: Principal Investigator

Collapse Bibliographic 
Collapse selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Ahmad S, Mora S, Franks PW, Orho-Melander M, Ridker PM, Hu FB, Chasman DI. Adiposity and Genetic Factors in Relation to Triglycerides and Triglyceride-Rich Lipoproteins in the Women's Genome Health Study. Clin Chem. 2017 Nov 02. PMID: 29097515.
    View in: PubMed
  2. Lawler PR, Mora S. Partitioning the Genetic Architecture of Plasma Lipoprotein(a) and Kringle IV Type 2 Repeats: Implications for Therapeutic Lowering. Clin Chem. 2017 Oct 16. PMID: 29038149.
    View in: PubMed
  3. van Capelleveen JC, Bochem AE, Boekholdt SM, Mora S, Hoogeveen RC, Ballantyne CM, Ridker PM, Sun W, Barter PJ, Tall AR, Zwinderman AH, Kastelein JJP, Wareham NJ, Khaw KT, Hovingh GK. Association of High-Density Lipoprotein-Cholesterol Versus Apolipoprotein A-I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer-Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study. J Am Heart Assoc. 2017 Aug 03; 6(8). PMID: 28775061.
    View in: PubMed
  4. Lawler PR, Akinkuolie AO, Chu AY, Shah SH, Kraus WE, Craig D, Padmanabhan L, Glynn RJ, Ridker PM, Chasman DI, Mora S. Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol. J Am Heart Assoc. 2017 Jul 21; 6(7). PMID: 28733430.
    View in: PubMed
  5. Tobias DK, Akinkuolie AO, Chandler PD, Lawler PR, Manson JE, Buring JE, Ridker PM, Wang L, Lee IM, Mora S. Markers of Inflammation and Incident Breast Cancer Risk in the Women's Health Study. Am J Epidemiol. 2017 Jun 21. PMID: 28641369.
    View in: PubMed
  6. Harada PHN, Demler OV, Dugani SB, Akinkuolie AO, Moorthy MV, Ridker PM, Cook NR, Pradhan AD, Mora S. Lipoprotein insulin resistance score and risk of incident diabetes during extended follow-up of 20 years: The Women's Health Study. J Clin Lipidol. 2017 Sep - Oct; 11(5):1257-1267.e2. PMID: 28733174.
    View in: PubMed
  7. Khera AV, Demler OV, Adelman SJ, Collins HL, Glynn RJ, Ridker PM, Rader DJ, Mora S. Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). Circulation. 2017 Jun 20; 135(25):2494-2504. PMID: 28450350.
    View in: PubMed
  8. Bell G, Mora S, Greenland P, Tsai M, Gill E, Kaufman JD. Association of Air Pollution Exposures With High-Density Lipoprotein Cholesterol and Particle Number: The Multi-Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol. 2017 May; 37(5):976-982. PMID: 28408373.
    View in: PubMed
  9. Wang Z, Manichukal A, Goff DC, Mora S, Ordovas JM, Pajewski NM, Post WS, Rotter JI, Sale MM, Santorico SA, Siscovick D, Tsai MY, Arnett DK, Rich S, Frazier-Wood AC. Genetic associations with lipoprotein subfraction measures differ by ethnicity in the multi-ethnic study of atherosclerosis (MESA). Hum Genet. 2017 Jun; 136(6):715-726. PMID: 28352986.
    View in: PubMed
  10. Keser T, Vuckovic F, Barrios C, Zierer J, Wahl A, Akinkuolie AO, Štambuk J, Nakic N, Pavic T, Periša J, Mora S, Gieger C, Menni C, Spector TD, Gornik O, Lauc G. Effects of statins on the immunoglobulin G glycome. Biochim Biophys Acta. 2017 05; 1861(5 Pt A):1152-1158. PMID: 28263871.
    View in: PubMed
  11. Ellervik C, Mora S. Predicting Asthma Exacerbations from a Drop of Blood. Clin Chem. 2017 Apr; 63(4):799-801. PMID: 28209626.
    View in: PubMed
  12. Lawler PR, Akinkuolie AO, Ridker PM, Sniderman AD, Buring JE, Glynn RJ, Chasman DI, Mora S. Discordance between Circulating Atherogenic Cholesterol Mass and Lipoprotein Particle Concentration in Relation to Future Coronary Events in Women. Clin Chem. 2017 Apr; 63(4):870-879. PMID: 28174174.
    View in: PubMed
  13. Mora S, Manson JE. Risk and Benefit Information and Use of Aspirin-Reply. JAMA Intern Med. 2017 Feb 01; 177(2):291-292. PMID: 28166350.
    View in: PubMed
  14. Harada PHN , Buring JE, Cook NR, Cobble ME, Kulkarni KR, Mora S. Impact of Subclinical Hypothyroidism on Cardiometabolic Biomarkers in Women. J. Endocr. Soc. (2017) 1 (2): 113-123. 2017.
  15. Harada PHN, Buring JE, Cook NR, Cobble ME, Kulkarni KR, Mora S. Impact of Subclinical Hypothyroidism on Cardiometabolic Biomarkers in Women. J Endocr Soc. 2017 Feb 01; 1(2):113-123. PMID: 28580441.
    View in: PubMed
  16. Mora S, Manson JE. Shared Decision Making Regarding Aspirin in Primary Prevention of Cardiovascular Disease-Reply. JAMA. 2016 Dec 06; 316(21):2276-2277. PMID: 27923086.
    View in: PubMed
  17. Chandler PD, Akinkuolie AO, Tobias DK, Lawler PR, Li C, Moorthy MV, Wang L, Duprez DA, Jacobs DR, Glynn RJ, Otvos J, Connelly MA, Post WS, Ridker PM, Manson JE, Buring JE, Lee IM, Mora S. Association of N-Linked Glycoprotein Acetyls and Colorectal Cancer Incidence and Mortality. PLoS One. 2016; 11(11):e0165615. PMID: 27902713.
    View in: PubMed
  18. Lawler PR, Mora S. Glycosylation Signatures of Inflammation Identify Cardiovascular Risk: Some Glyc It Hot. Circ Res. 2016 Nov 11; 119(11):1154-1156. PMID: 28051777.
    View in: PubMed
  19. Farukhi Z, Mora S. Re-assessing the role of non-fasting lipids; a change in perspective. Ann Transl Med. 2016 Nov; 4(21):431. PMID: 27942522.
    View in: PubMed
  20. Aldasouqi S, Corser W, Abela GS, Mora S, Shahar K, Krishnan P, Bhatti F, Hsu A, Gruenebaum D. Fasting for laboratory tests poses a high risk of hypoglycemia in patients with diabetes: A pilot prevalence study in clinical practice. Int J Clin Med;7:653-677. 2016.
  21. Mora S, Ames JM, Manson JE. Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease: Shared Decision Making in Clinical Practice. JAMA. 2016 Aug 16; 316(7):709-10. PMID: 27323335.
    View in: PubMed
  22. Mora S, Manson JE. Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease: Advances in Diagnosis and Treatment. JAMA Intern Med. 2016 Aug 01; 176(8):1195-204. PMID: 27322595.
    View in: PubMed
  23. Akinkuolie AO, Glynn RJ, Padmanabhan L, Ridker PM, Mora S. Circulating N-Linked Glycoprotein Side-Chain Biomarker, Rosuvastatin Therapy, and Incident Cardiovascular Disease: An Analysis From the JUPITER Trial. J Am Heart Assoc. 2016 Jul 13; 5(7). PMID: 27413042.
    View in: PubMed
  24. Mora S. Nonfasting for Routine Lipid Testing: From Evidence to Action. JAMA Intern Med. 2016 Jul 01; 176(7):1005-6. PMID: 27119719.
    View in: PubMed
  25. Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E, Watts GF, Sypniewska G, Wiklund O, Borén J, Chapman MJ, Cobbaert C, Descamps OS, von Eckardstein A, Kamstrup PR, Pulkki K, Kronenberg F, Remaley AT, Rifai N, Ros E, Langlois M. Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cutpoints-A Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Clin Chem. 2016 Jul; 62(7):930-46. PMID: 27235445.
    View in: PubMed
  26. Dugani SB, Akinkuolie AO, Paynter N, Glynn RJ, Ridker PM, Mora S. Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2016 May 01; 1(2):136-45. PMID: 27347563; PMCID: PMC4918085 [Available on 05/01/17].
  27. Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E, Watts GF, Sypniewska G, Wiklund O, Borén J, Chapman MJ, Cobbaert C, Descamps OS, von Eckardstein A, Kamstrup PR, Pulkki K, Kronenberg F, Remaley AT, Rifai N, Ros E, Langlois M. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J. 2016 Jul 01; 37(25):1944-58. PMID: 27122601; PMCID: PMC4929379.
  28. Farukhi Z, Mora S. Lowering LDL Cholesterol: When Numbers are Not Enough. http://www.acc.org/. Apr 13, 2016. Accessed May 21, 2016. http://www.acc.org/latest-in-cardiology/articles/2016/04/13/07/27/lowering-ldl-cholesterol. 2016.
  29. Chandler PD, Song Y, Lin J, Zhang S, Sesso HD, Mora S, Giovannucci EL, Rexrode KE, Moorthy MV, Li C, Ridker PM, Lee IM, Manson JE, Buring JE, Wang L. Lipid biomarkers and long-term risk of cancer in the Women's Health Study. Am J Clin Nutr. 2016 Jun; 103(6):1397-407. PMID: 27099252; PMCID: PMC4880994 [Available on 06/01/17].
  30. Tehrani DM, Zhao Y, Blaha MJ, Mora S, Mackey RH, Michos ED, Budoff MJ, Cromwell W, Otvos JD, Rosenblit PD, Wong ND. Discordance of Low-Density Lipoprotein and High-Density Lipoprotein Cholesterol Particle Versus Cholesterol Concentration for the Prediction of Cardiovascular Disease in Patients With Metabolic Syndrome and Diabetes Mellitus (from the Multi-Ethnic Study of Atherosclerosis [MESA]). Am J Cardiol. 2016 Jun 15; 117(12):1921-7. PMID: 27156827.
    View in: PubMed
  31. Lawler PR, Akinkuolie AO, Chandler PD, Moorthy MV, Vandenburgh MJ, Schaumberg DA, Lee IM, Glynn RJ, Ridker PM, Buring JE, Mora S. Circulating N-Linked Glycoprotein Acetyls and Longitudinal Mortality Risk. Circ Res. 2016 Apr 01; 118(7):1106-15. PMID: 26951635; PMCID: PMC4836171 [Available on 04/01/17].
  32. Ridker PM, Mora S, Rose L. Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. Eur Heart J. 2016 May 01; 37(17):1373-9. PMID: 26916794; PMCID: PMC4852064 [Available on 05/01/17].
  33. Rifai N, Young IS, Nordestgaard BG, Wierzbicki AS, Vesper H, Mora S, Stone NJ, Genest J, Miller G. Nonfasting Sample for the Determination of Routine Lipid Profile: Is It an Idea Whose Time Has Come? Clin Chem. 2016 Mar; 62(3):428-35. PMID: 26787760.
    View in: PubMed
  34. Mora S, Caulfield MP, Wohlgemuth J, Chen Z, Superko HR, Rowland CM, Glynn RJ, Ridker PM, Krauss RM. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial. Circulation. 2015 Dec 08; 132(23):2220-9. PMID: 26408274; PMCID: PMC4674425 [Available on 12/08/16].
  35. Chu AY, Giulianini F, Barratt BJ, Ding B, Nyberg F, Mora S, Ridker PM, Chasman DI. Differential Genetic Effects on Statin-Induced Changes Across Low-Density Lipoprotein-Related Measures. Circ Cardiovasc Genet. 2015 Oct; 8(5):688-95. PMID: 26273092; PMCID: PMC4618030 [Available on 10/01/16].
  36. White KT, Moorthy MV, Akinkuolie AO, Demler O, Ridker PM, Cook NR, Mora S. Identifying an Optimal Cutpoint for the Diagnosis of Hypertriglyceridemia in the Nonfasting State. Clin Chem. 2015 Sep; 61(9):1156-63. PMID: 26071491; PMCID: PMC4554926 [Available on 09/01/16].
  37. Doran B, Guo Y, Xu J, Weintraub H, Mora S, Maron DJ, Bangalore S. Reply to Letters Regarding Article, "Prognostic Value of Fasting Versus Nonfasting Low-Density Lipoprotein Cholesterol Levels on Long-Term Mortality: Insight From the National Health and Nutrition Examination Survey III (NHANES-III)". Circulation. 2015 May 12; 131(19):e473. PMID: 25964286.
    View in: PubMed
  38. Akinkuolie AO, Pradhan AD, Buring JE, Ridker PM, Mora S. Novel protein glycan side-chain biomarker and risk of incident type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2015 Jun; 35(6):1544-50. PMID: 25908766; PMCID: PMC4441588 [Available on 06/01/16].
  39. Shim H, Chasman DI, Smith JD, Mora S, Ridker PM, Nickerson DA, Krauss RM, Stephens M. A multivariate genome-wide association analysis of 10 LDL subfractions, and their response to statin treatment, in 1868 Caucasians. PLoS One. 2015; 10(4):e0120758. PMID: 25898129; PMCID: PMC4405269.
  40. Mackey RH, Mora S, Bertoni AG, Wassel CL, Carnethon MR, Sibley CT, Goff DC. Lipoprotein particles and incident type 2 diabetes in the multi-ethnic study of atherosclerosis. Diabetes Care. 2015 Apr; 38(4):628-36. PMID: 25592196; PMCID: PMC4370328 [Available on 04/01/16].
  41. Shah AM, Mora S. In: Wong ND, Amsterdam EA, Blumenthal RS, editors. ASPC Manual of Preventive Cardiology. Chapter 12. Role of Stress Testing. 2014.
  42. Khera AV, Everett BM, Caulfield MP, Hantash FM, Wohlgemuth J, Ridker PM, Mora S. Response to letter regarding article, "lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)". Circulation. 2014 Oct 21; 130(17):e152. PMID: 25332285.
    View in: PubMed
  43. Akinkuolie AO, Buring JE, Ridker PM, Mora S. A novel protein glycan biomarker and future cardiovascular disease events. J Am Heart Assoc. 2014 Sep 23; 3(5):e001221. PMID: 25249300; PMCID: PMC4323825.
  44. Everett BM, Mora S, Glynn RJ, MacFadyen J, Ridker PM. Safety profile of subjects treated to very low low-density lipoprotein cholesterol levels (<30 mg/dl) with rosuvastatin 20 mg daily (from JUPITER). Am J Cardiol. 2014 Dec 01; 114(11):1682-9. PMID: 25439449.
    View in: PubMed
  45. Lawler PR, Mora S. Moving beyond mean glycemia: 1,5-anhydroglucitol and microvascular complications of diabetes. Clin Chem. 2014 Nov; 60(11):1359-61. PMID: 25217368.
    View in: PubMed
  46. Harada PHN, Akinkulolie AO, Mora S. Advanced lipoprotein testing: Strengths and limitations.http://ldl.cardiosource.org/Hot-Topics/2014/08/Advanced-Lipoprotein-Testing.aspx. 2014.
  47. Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, LaRosa JC, Waters DD, DeMicco DA, Simes RJ, Keech AC, Colquhoun D, Hitman GA, Betteridge DJ, Clearfield MB, Downs JR, Colhoun HM, Gotto AM, Ridker PM, Grundy SM, Kastelein JJ. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol. 2014 Aug 05; 64(5):485-94. PMID: 25082583; PMCID: PMC4443441.
  48. Doran B, Guo Y, Xu J, Weintraub H, Mora S, Maron DJ, Bangalore S. Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: insight from the National Health and Nutrition Examination Survey III (NHANES-III). Circulation. 2014 Aug 12; 130(7):546-53. PMID: 25015340.
    View in: PubMed
  49. Mora S, Akinkuolie AO, Sandhu RK, Conen D, Albert CM. Paradoxical association of lipoprotein measures with incident atrial fibrillation. Circ Arrhythm Electrophysiol. 2014 Aug; 7(4):612-9. PMID: 24860180; PMCID: PMC4591535.
  50. Harrington C, Mora S, Wu KC. In: Yuh DD, Vricella LA, Yang S, Doty J, editors. The Johns Hopkins Manual of Cardiothoracic Surgery, 2nd edition. Chapter 56. Echocardiography in cardiac surgery. 2014.
  51. Mora S, Glynn RJ, Ridker PM. Response to letter regarding article, "High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy". Circulation. 2014 Apr 29; 129(17):e481. PMID: 24778127; PMCID: PMC4584403.
  52. D'Agostino RB, Ansell BJ, Mora S, Krumholz HM. Clinical decisions. The guidelines battle on starting statins. N Engl J Med. 2014 Apr 24; 370(17):1652-8. PMID: 24758622.
    View in: PubMed
  53. Mora S. HDL cholesterol, size, particle number. In: Braunwald E, editor. Braunwald’s Heart Disease, on-line edition. Philadelphia: Elsevier Saunders. https://expertconsult.inkling.com/. 2014.
  54. Arsenault BJ, Boekholdt SM, Mora S, DeMicco DA, Bao W, Tardif JC, Amarenco P, Pedersen T, Barter P, Waters DD. Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL). Am J Cardiol. 2014 Apr 15; 113(8):1378-82. PMID: 24582532.
    View in: PubMed
  55. Gronowski AM, Manson JE, Mardis ER, Mora S, Spong CY. What's different about women's health? Clin Chem. 2014 Jan; 60(1):1-3. PMID: 24379307.
    View in: PubMed
  56. Mora S, Buring JE, Ridker PM. Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. Circulation. 2014 Feb 04; 129(5):553-61. PMID: 24345402; PMCID: PMC4501252.
  57. Akinkuolie AO, Paynter NP, Padmanabhan L, Mora S. High-density lipoprotein particle subclass heterogeneity and incident coronary heart disease. Circ Cardiovasc Qual Outcomes. 2014 Jan; 7(1):55-63. PMID: 24248942; PMCID: PMC4052434.
  58. Khera AV, Everett BM, Caulfield MP, Hantash FM, Wohlgemuth J, Ridker PM, Mora S. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation. 2014 Feb 11; 129(6):635-42. PMID: 24243886; PMCID: PMC3946056.
  59. Akinkuolie AO, Mora S. Are there sex differences in acute coronary syndrome presentation?: a guide through the maze. JAMA Intern Med. 2013 Nov 11; 173(20):1861-2. PMID: 24042698; PMCID: PMC3830727.
  60. Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, Gustafsson S, Kanoni S, Ganna A, Chen J, Buchkovich ML, Mora S, Beckmann JS, Bragg-Gresham JL, Chang HY, Demirkan A, Den Hertog HM, Donnelly LA, Ehret GB, Esko T, Feitosa MF, Ferreira T, Fischer K, Fontanillas P, Fraser RM, Freitag DF, Gurdasani D, Heikkilä K, Hyppönen E, Isaacs A, Jackson AU, Johansson A, Johnson T, Kaakinen M, Kettunen J, Kleber ME, Li X, Luan J, Lyytikäinen LP, Magnusson PK, Mangino M, Mihailov E, Montasser ME, Müller-Nurasyid M, Nolte IM, O'Connell JR, Palmer CD, Perola M, Petersen AK, Sanna S, Saxena R, Service SK, Shah S, Shungin D, Sidore C, Song C, Strawbridge RJ, Surakka I, Tanaka T, Teslovich TM, Thorleifsson G, Van den Herik EG, Voight BF, Volcik KA, Waite LL, Wong A, Wu Y, Zhang W, Absher D, Asiki G, Barroso I, Been LF, Bolton JL, Bonnycastle LL, Brambilla P, Burnett MS, Cesana G, Dimitriou M, Doney AS, Döring A, Elliott P, Epstein SE, Eyjolfsson GI, Gigante B, Goodarzi MO, Grallert H, Gravito ML, Groves CJ, Hallmans G, Hartikainen AL, Hayward C, Hernandez D, Hicks AA, Holm H, Hung YJ, Illig T, Jones MR, Kaleebu P, Kastelein JJ, Khaw KT, Kim E, Klopp N, Komulainen P, Kumari M, Langenberg C, Lehtimäki T, Lin SY, Lindström J, Loos RJ, Mach F, McArdle WL, Meisinger C, Mitchell BD, Müller G, Nagaraja R, Narisu N, Nieminen TV, Nsubuga RN, Olafsson I, Ong KK, Palotie A, Papamarkou T, Pomilla C, Pouta A, Rader DJ, Reilly MP, Ridker PM, Rivadeneira F, Rudan I, Ruokonen A, Samani N, Scharnagl H, Seeley J, Silander K, Stancáková A, Stirrups K, Swift AJ, Tiret L, Uitterlinden AG, van Pelt LJ, Vedantam S, Wainwright N, Wijmenga C, Wild SH, Willemsen G, Wilsgaard T, Wilson JF, Young EH, Zhao JH, Adair LS, Arveiler D, Assimes TL, Bandinelli S, Bennett F, Bochud M, Boehm BO, Boomsma DI, Borecki IB, Bornstein SR, Bovet P, Burnier M, Campbell H, Chakravarti A, Chambers JC, Chen YD, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Feranil AB, Ferrières J, Ferrucci L, Freimer NB, Gieger C, Groop LC, Gudnason V, Gyllensten U, Hamsten A, Harris TB, Hingorani A, Hirschhorn JN, Hofman A, Hovingh GK, Hsiung CA, Humphries SE, Hunt SC, Hveem K, Iribarren C, Järvelin MR, Jula A, Kähönen M, Kaprio J, Kesäniemi A, Kivimaki M, Kooner JS, Koudstaal PJ, Krauss RM, Kuh D, Kuusisto J, Kyvik KO, Laakso M, Lakka TA, Lind L, Lindgren CM, Martin NG, März W, McCarthy MI, McKenzie CA, Meneton P, Metspalu A, Moilanen L, Morris AD, Munroe PB, Njølstad I, Pedersen NL, Power C, Pramstaller PP, Price JF, Psaty BM, Quertermous T, Rauramaa R, Saleheen D, Salomaa V, Sanghera DK, Saramies J, Schwarz PE, Sheu WH, Shuldiner AR, Siegbahn A, Spector TD, Stefansson K, Strachan DP, Tayo BO, Tremoli E, Tuomilehto J, Uusitupa M, van Duijn CM, Vollenweider P, Wallentin L, Wareham NJ, Whitfield JB, Wolffenbuttel BH, Altshuler D, Ordovas JM, Boerwinkle E, Palmer CN, Thorsteinsdottir U, Chasman DI, Rotter JI, Franks PW, Ripatti S, Cupples LA, Sandhu MS, Rich SS, Boehnke M, Deloukas P, Mohlke KL, Ingelsson E, Abecasis GR, Daly MJ, Neale BM, Kathiresan S. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013 Nov; 45(11):1345-52. PMID: 24097064; PMCID: PMC3904346.
  61. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, Ganna A, Chen J, Buchkovich ML, Mora S, Beckmann JS, Bragg-Gresham JL, Chang HY, Demirkan A, Den Hertog HM, Do R, Donnelly LA, Ehret GB, Esko T, Feitosa MF, Ferreira T, Fischer K, Fontanillas P, Fraser RM, Freitag DF, Gurdasani D, Heikkilä K, Hyppönen E, Isaacs A, Jackson AU, Johansson Å, Johnson T, Kaakinen M, Kettunen J, Kleber ME, Li X, Luan J, Lyytikäinen LP, Magnusson PKE, Mangino M, Mihailov E, Montasser ME, Müller-Nurasyid M, Nolte IM, O'Connell JR, Palmer CD, Perola M, Petersen AK, Sanna S, Saxena R, Service SK, Shah S, Shungin D, Sidore C, Song C, Strawbridge RJ, Surakka I, Tanaka T, Teslovich TM, Thorleifsson G, Van den Herik EG, Voight BF, Volcik KA, Waite LL, Wong A, Wu Y, Zhang W, Absher D, Asiki G, Barroso I, Been LF, Bolton JL, Bonnycastle LL, Brambilla P, Burnett MS, Cesana G, Dimitriou M, Doney ASF, Döring A, Elliott P, Epstein SE, Ingi Eyjolfsson G, Gigante B, Goodarzi MO, Grallert H, Gravito ML, Groves CJ, Hallmans G, Hartikainen AL, Hayward C, Hernandez D, Hicks AA, Holm H, Hung YJ, Illig T, Jones MR, Kaleebu P, Kastelein JJP, Khaw KT, Kim E, Klopp N, Komulainen P, Kumari M, Langenberg C, Lehtimäki T, Lin SY, Lindström J, Loos RJF, Mach F, McArdle WL, Meisinger C, Mitchell BD, Müller G, Nagaraja R, Narisu N, Nieminen TVM, Nsubuga RN, Olafsson I, Ong KK, Palotie A, Papamarkou T, Pomilla C, Pouta A, Rader DJ, Reilly MP, Ridker PM, Rivadeneira F, Rudan I, Ruokonen A, Samani N, Scharnagl H, Seeley J, Silander K, Stancáková A, Stirrups K, Swift AJ, Tiret L, Uitterlinden AG, van Pelt LJ, Vedantam S, Wainwright N, Wijmenga C, Wild SH, Willemsen G, Wilsgaard T, Wilson JF, Young EH, Zhao JH, Adair LS, Arveiler D, Assimes TL, Bandinelli S, Bennett F, Bochud M, Boehm BO, Boomsma DI, Borecki IB, Bornstein SR, Bovet P, Burnier M, Campbell H, Chakravarti A, Chambers JC, Chen YI, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Feranil AB, Ferrières J, Ferrucci L, Freimer NB, Gieger C, Groop LC, Gudnason V, Gyllensten U, Hamsten A, Harris TB, Hingorani A, Hirschhorn JN, Hofman A, Hovingh GK, Hsiung CA, Humphries SE, Hunt SC, Hveem K, Iribarren C, Järvelin MR, Jula A, Kähönen M, Kaprio J, Kesäniemi A, Kivimaki M, Kooner JS, Koudstaal PJ, Krauss RM, Kuh D, Kuusisto J, Kyvik KO, Laakso M, Lakka TA, Lind L, Lindgren CM, Martin NG, März W, McCarthy MI, McKenzie CA, Meneton P, Metspalu A, Moilanen L, Morris AD, Munroe PB, Njølstad I, Pedersen NL, Power C, Pramstaller PP, Price JF, Psaty BM, Quertermous T, Rauramaa R, Saleheen D, Salomaa V, Sanghera DK, Saramies J, Schwarz PEH, Sheu WH, Shuldiner AR, Siegbahn A, Spector TD, Stefansson K, Strachan DP, Tayo BO, Tremoli E, Tuomilehto J, Uusitupa M, van Duijn CM, Vollenweider P, Wallentin L, Wareham NJ, Whitfield JB, Wolffenbuttel BHR, Ordovas JM, Boerwinkle E, Palmer CNA, Thorsteinsdottir U, Chasman DI, Rotter JI, Franks PW, Ripatti S, Cupples LA, Sandhu MS, Rich SS, Boehnke M, Deloukas P, Kathiresan S, Mohlke KL, Ingelsson E, Abecasis GR. Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013 Nov; 45(11):1274-1283. PMID: 24097068; PMCID: PMC3838666.
  62. Mora S, Glynn RJ, Ridker PM. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation. 2013 Sep 10; 128(11):1189-97. PMID: 24002795; PMCID: PMC3807967.
  63. Boekholdt SM, Arsenault BJ, Hovingh GK, Mora S, Pedersen TR, Larosa JC, Welch KM, Amarenco P, Demicco DA, Tonkin AM, Sullivan DR, Kirby A, Colhoun HM, Hitman GA, Betteridge DJ, Durrington PN, Clearfield MB, Downs JR, Gotto AM, Ridker PM, Kastelein JJ. Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. Circulation. 2013 Oct 01; 128(14):1504-12. PMID: 23965489; PMCID: PMC3807966.
  64. Thomas D, Al-Mallah M, Govindarajulu U, Forman DE, Mora S, Di Carli MF, Dorbala S. Value of reserve pulse pressure in improving the risk stratification of patients with normal myocardial perfusion imaging. Eur Heart J. 2013 Jul; 34(27):2074-81a. PMID: 23539339; PMCID: PMC3710579.
  65. Mazer NA, Giulianini F, Paynter NP, Jordan P, Mora S. A comparison of the theoretical relationship between HDL size and the ratio of HDL cholesterol to apolipoprotein A-I with experimental results from the Women's Health Study. Clin Chem. 2013 Jun; 59(6):949-58. PMID: 23426429; PMCID: PMC3669243.
  66. Khera AV, Mora S. Fasting for lipid testing: Is it worth the trouble? Arch Intern Med. 2012 Dec 10; 172(22):1710-2. PMID: 23405395.
    View in: PubMed
  67. Ndumele CE, Matsushita K, Astor B, Virani SS, Mora S, Williams EK, Hoogeveen RC, Blumenthal RS, Sharrett AR, Ballantyne CM, Coresh J. Apolipoproteins do not add prognostic information beyond lipoprotein cholesterol measures among individuals with obesity and insulin resistance syndromes: the ARIC study. Eur J Prev Cardiol. 2014 Jul; 21(7):866-75. PMID: 23109406.
    View in: PubMed
  68. Mackey RH, Greenland P, Goff DC, Lloyd-Jones D, Sibley CT, Mora S. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J Am Coll Cardiol. 2012 Aug 07; 60(6):508-16. PMID: 22796256; PMCID: PMC3411890.
  69. Mora S, Glynn RJ, Boekholdt SM, Nordestgaard BG, Kastelein JJ, Ridker PM. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). J Am Coll Cardiol. 2012 Apr 24; 59(17):1521-8. PMID: 22516441; PMCID: PMC3338194.
  70. Lieber SB, Redberg RF, Blumenthal RS, Gandhi A, Robb KJ, Mora S. A national interactive web-based physical activity intervention in women, evaluation of the american heart association choose to move program 2006-2007. Am J Cardiol. 2012 Jun 15; 109(12):1754-60. PMID: 22494850.
    View in: PubMed
  71. Mora S, Wenger NK, Demicco DA, Breazna A, Boekholdt SM, Arsenault BJ, Deedwania P, Kastelein JJ, Waters DD. Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study. Circulation. 2012 Apr 24; 125(16):1979-87. PMID: 22461416; PMCID: PMC3338158.
  72. Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, Simes RJ, Durrington P, Hitman GA, Welch KM, DeMicco DA, Zwinderman AH, Clearfield MB, Downs JR, Tonkin AM, Colhoun HM, Gotto AM, Ridker PM, Kastelein JJ. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012 Mar 28; 307(12):1302-9. PMID: 22453571.
    View in: PubMed
  73. Mora S. Non-fasting blood testing for lipid screening in children result in statistically significant, but not clinically significant, changes in lipid levels. Evid Based Med. 2012 Aug; 17(4):133-4. PMID: 22293340.
    View in: PubMed
  74. Mora S. Aspirin therapy in primary prevention: comment on "effect of aspirin on vascular and nonvascular outcomes". Arch Intern Med. 2012 Feb 13; 172(3):217-8. PMID: 22231608.
    View in: PubMed
  75. Graham G, Ketlogetswe K, Campbell CY, Musunuru K, Mora S, Blumenthal RS. Use of high sensitivity C-reactive protein for risk assessment. In: Baliga RR and Cannon CP, editors. Dyslipidemia. Oxford University Press, NY, NY; 67-86. 2012.
  76. Mora S, Buring JE, Ridker PM, Cui Y. Association of high-density lipoprotein cholesterol with incident cardiovascular events in women, by low-density lipoprotein cholesterol and apolipoprotein B100 levels: a cohort study. Ann Intern Med. 2011 Dec 06; 155(11):742-50. PMID: 22147713; PMCID: PMC3233986.
  77. Kilpeläinen TO, Qi L, Brage S, Sharp SJ, Sonestedt E, Demerath E, Ahmad T, Mora S, Kaakinen M, Sandholt CH, Holzapfel C, Autenrieth CS, Hyppönen E, Cauchi S, He M, Kutalik Z, Kumari M, Stancáková A, Meidtner K, Balkau B, Tan JT, Mangino M, Timpson NJ, Song Y, Zillikens MC, Jablonski KA, Garcia ME, Johansson S, Bragg-Gresham JL, Wu Y, van Vliet-Ostaptchouk JV, Onland-Moret NC, Zimmermann E, Rivera NV, Tanaka T, Stringham HM, Silbernagel G, Kanoni S, Feitosa MF, Snitker S, Ruiz JR, Metter J, Larrad MT, Atalay M, Hakanen M, Amin N, Cavalcanti-Proença C, Grøntved A, Hallmans G, Jansson JO, Kuusisto J, Kähönen M, Lutsey PL, Nolan JJ, Palla L, Pedersen O, Pérusse L, Renström F, Scott RA, Shungin D, Sovio U, Tammelin TH, Rönnemaa T, Lakka TA, Uusitupa M, Rios MS, Ferrucci L, Bouchard C, Meirhaeghe A, Fu M, Walker M, Borecki IB, Dedoussis GV, Fritsche A, Ohlsson C, Boehnke M, Bandinelli S, van Duijn CM, Ebrahim S, Lawlor DA, Gudnason V, Harris TB, Sørensen TI, Mohlke KL, Hofman A, Uitterlinden AG, Tuomilehto J, Lehtimäki T, Raitakari O, Isomaa B, Njølstad PR, Florez JC, Liu S, Ness A, Spector TD, Tai ES, Froguel P, Boeing H, Laakso M, Marmot M, Bergmann S, Power C, Khaw KT, Chasman D, Ridker P, Hansen T, Monda KL, Illig T, Järvelin MR, Wareham NJ, Hu FB, Groop LC, Orho-Melander M, Ekelund U, Franks PW, Loos RJ. Physical activity attenuates the influence of FTO variants on obesity risk: a meta-analysis of 218,166 adults and 19,268 children. PLoS Med. 2011 Nov; 8(11):e1001116. PMID: 22069379; PMCID: PMC3206047.
  78. Paynter NP, Sesso HD, Conen D, Otvos JD, Mora S. Lipoprotein subclass abnormalities and incident hypertension in initially healthy women. Clin Chem. 2011 Aug; 57(8):1178-87. PMID: 21700954; PMCID: PMC3153909.
  79. Otvos JD, Mora S, Shalaurova I, Greenland P, Mackey RH, Goff DC. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol. 2011 Mar-Apr; 5(2):105-13. PMID: 21392724; PMCID: PMC3070150.
  80. Ahmad T, Lee IM, Paré G, Chasman DI, Rose L, Ridker PM, Mora S. Lifestyle interaction with fat mass and obesity-associated (FTO) genotype and risk of obesity in apparently healthy U.S. women. Diabetes Care. 2011 Mar; 34(3):675-80. PMID: 21266646; PMCID: PMC3041206.
  81. Shah AM, Mora S. Exercise treadmill stress testing with and without imaging. Prevention of Cardiovascular Disease: A Companion to Braunwald’s Heart Disease. 2011; 477-490.
  82. Ahmad T, Chasman DI, Mora S, Paré G, Cook NR, Buring JE, Ridker PM, Lee IM. The fat-mass and obesity-associated (FTO) gene, physical activity, and risk of incident cardiovascular events in white women. Am Heart J. 2010 Dec; 160(6):1163-9. PMID: 21146673; PMCID: PMC3058560.
  83. Ridker PM, Genest J, Boekholdt SM, Libby P, Gotto AM, Nordestgaard BG, Mora S, MacFadyen JG, Glynn RJ, Kastelein JJ. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet. 2010 Jul 31; 376(9738):333-9. PMID: 20655105.
    View in: PubMed
  84. Mora S, Kamstrup PR, Rifai N, Nordestgaard BG, Buring JE, Ridker PM. Lipoprotein(a) and risk of type 2 diabetes. Clin Chem. 2010 Aug; 56(8):1252-60. PMID: 20511445; PMCID: PMC2912456.
  85. Weiss SA, Blumenthal RS, Sharrett AR, Redberg RF, Mora S. Exercise blood pressure and future cardiovascular death in asymptomatic individuals. Circulation. 2010 May 18; 121(19):2109-16. PMID: 20439788; PMCID: PMC2894617.
  86. Mora S, Otvos JD, Rosenson RS, Pradhan A, Buring JE, Ridker PM. Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women. Diabetes. 2010 May; 59(5):1153-60. PMID: 20185808; PMCID: PMC2857895.
  87. Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation. 2010 Mar 09; 121(9):1069-77. PMID: 20176986; PMCID: PMC4439924.
  88. Ahmad T, Mora S. Providing patients with global cardiovascular risk information: is knowledge power? Arch Intern Med. 2010 Feb 08; 170(3):227-8. PMID: 20142566; PMCID: PMC2856346.
  89. Musunuru K, Blumenthal RS, Mora S. C-reactive protein and cardiovascular disease. The clinical utility of C-reactive protein in cardiovascular disease. 2010; 157-174.
  90. Musunuru K, Mora S. The Johns Hopkins Textbook of Dyslipidemia. Clinical Utility of Inflammatory Markers. 2010; 183-195.
  91. Chasman DI, Paré G, Mora S, Hopewell JC, Peloso G, Clarke R, Cupples LA, Hamsten A, Kathiresan S, Mälarstig A, Ordovas JM, Ripatti S, Parker AN, Miletich JP, Ridker PM. Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. PLoS Genet. 2009 Nov; 5(11):e1000730. PMID: 19936222; PMCID: PMC2777390.
  92. Redberg RF, Benjamin EJ, Bittner V, Braun LT, Goff DC, Havas S, Labarthe DR, Limacher MC, Lloyd-Jones DM, Mora S, Pearson TA, Radford MJ, Smetana GW, Spertus JA, Swegler EW. ACCF/AHA 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for Primary Prevention of Cardiovascular Disease) developed in collaboration with the American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; and Preventive Cardiovascular Nurses Association: endorsed by the American College of Preventive Medicine, American College of Sports Medicine, and Society for Women's Health Research. J Am Coll Cardiol. 2009 Sep 29; 54(14):1364-405. PMID: 19778679.
    View in: PubMed
  93. Redberg RF, Benjamin EJ, Bittner V, Braun LT, Goff DC, Havas S, Labarthe DR, Limacher MC, Lloyd-Jones DM, Mora S, Pearson TA, Radford MJ, Smetana GW, Spertus JA, Swegler EW. AHA/ACCF [corrected] 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on performance measures (writing committee to develop performance measures for primary prevention of cardiovascular disease): developed in collaboration with the American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; and Preventive Cardiovascular Nurses Association: endorsed by the American College of Preventive Medicine, American College of Sports Medicine, and Society for Women's Health Research. Circulation. 2009 Sep 29; 120(13):1296-336. PMID: 19770388.
    View in: PubMed
  94. Moukarbel GV, Shah AM, Tinnemore A, Mora S. Biphasic pulmonary regurgitation. Echocardiography. 2009 Jul; 26(6):720-3. PMID: 19594819.
    View in: PubMed
  95. Mora S. Advanced lipoprotein testing and subfractionation are not (yet) ready for routine clinical use. Circulation. 2009 May 05; 119(17):2396-404. PMID: 19414657; PMCID: PMC2735461.
  96. Mora S, Rifai N, Buring JE, Ridker PM. Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women. Clin Chem. 2009 May; 55(5):888-94. PMID: 19395440; PMCID: PMC2692888.
  97. Mora S. Aspirin therapy in women: back to the ABCs. Circ Cardiovasc Qual Outcomes. 2009 Mar; 2(2):63-4. PMID: 20031816.
    View in: PubMed
  98. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation. 2009 Feb 24; 119(7):931-9. PMID: 19204302; PMCID: PMC2663974.
  99. Mora S. Circulation: Cardiovascular Quality and Outcomes. Aspirin Therapy in Women: Back to the ABCs. 2009; 2:63-64.
  100. Campbell CY, Musunuru K, Mora S, Blumenthal RS. Clinical Lipidology: A Companion to Braunwald’s Heart Disease. Use of high sensitivity C-reactive protein for risk assessment. 2009; 158-166.
  101. Mora S, Musunuru K, Blumenthal RS. The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines. Clin Chem. 2009 Feb; 55(2):219-28. PMID: 19095730.
    View in: PubMed
  102. Musunuru K, Kral BG, Blumenthal RS, Fuster V, Campbell CY, Gluckman TJ, Lange RA, Topol EJ, Willerson JT, Desai MY, Davidson MH, Mora S. The use of high-sensitivity assays for C-reactive protein in clinical practice. Nat Clin Pract Cardiovasc Med. 2008 Oct; 5(10):621-35. PMID: 18711404; PMCID: PMC2639398.
  103. Mora S, Rifai N, Buring JE, Ridker PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation. 2008 Sep 02; 118(10):993-1001. PMID: 18711012; PMCID: PMC2574817.
  104. Mora S, Cook N, Buring JE, Ridker PM, Lee IM. Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms. Circulation. 2007 Nov 06; 116(19):2110-8. PMID: 17967770; PMCID: PMC2117381.
  105. Conen D, Ridker PM, Mora S, Buring JE, Glynn RJ. Blood pressure and risk of developing type 2 diabetes mellitus: the Women's Health Study. Eur Heart J. 2007 Dec; 28(23):2937-43. PMID: 17925342.
    View in: PubMed
  106. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007 Jul 18; 298(3):309-16. PMID: 17635891.
    View in: PubMed
  107. Mora S, Szklo M, Otvos JD, Greenland P, Psaty BM, Goff DC, O'Leary DH, Saad MF, Tsai MY, Sharrett AR. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2007 May; 192(1):211-7. PMID: 16765964.
    View in: PubMed
  108. Becker DM, Mora S, Goff DC. Biomarkers for prediction of cardiovascular events. N Engl J Med. 2007 Apr 05; 356(14):1473; author reply 1474-5. PMID: 17415902.
    View in: PubMed
  109. Zee RY, Mora S, Cheng S, Erlich HA, Lindpaintner K, Rifai N, Buring JE, Ridker PM. Homocysteine, 5,10-methylenetetrahydrofolate reductase 677C>T polymorphism, nutrient intake, and incident cardiovascular disease in 24,968 initially healthy women. Clin Chem. 2007 May; 53(5):845-51. PMID: 17332146.
    View in: PubMed
  110. Redberg RF, Mora S, Barbour DJ. American College of Obstetricians and Gynecologists Clinical Updates in Women’s Health Care. Chest pain and heart disease. 2007; VI(1):1-83.
  111. Mora S, Wu KC. The Johns Hopkins Manual of Cardiothoracic Surgery. Echocardiography in cardiac surgery. 2007; 943-68.
  112. D'Amore S, Mora S. Gender-specific prediction of cardiac disease: importance of risk factors and exercise variables. Cardiol Rev. 2006 Nov-Dec; 14(6):281-5. PMID: 17053374.
    View in: PubMed
  113. Schneider JG, Tompkins C, Blumenthal RS, Mora S. The metabolic syndrome in women. Cardiol Rev. 2006 Nov-Dec; 14(6):286-91. PMID: 17053375.
    View in: PubMed
  114. Mora S, Rifai N, Buring JE, Ridker PM. Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events. Circulation. 2006 Aug 01; 114(5):381-7. PMID: 16864722.
    View in: PubMed
  115. Reynolds SS, Yanek LR, Vaidya D, Mora S, Moy TF, Saudek CD, Becker LC, Becker DM. Glucose levels in the normal range predict incident diabetes in families with premature coronary heart disease. Diabetes Res Clin Pract. 2006 Dec; 74(3):267-73. PMID: 16716444.
    View in: PubMed
  116. Mora S, Lee IM, Buring JE, Ridker PM. Association of physical activity and body mass index with novel and traditional cardiovascular biomarkers in women. JAMA. 2006 Mar 22; 295(12):1412-9. PMID: 16551713.
    View in: PubMed
  117. Mora S, Ridker PM. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol. 2006 Jan 16; 97(2A):33A-41A. PMID: 16442935.
    View in: PubMed
  118. Mora S, Redberg RF, Sharrett AR, Blumenthal RS. Enhanced risk assessment in asymptomatic individuals with exercise testing and Framingham risk scores. Circulation. 2005 Sep 13; 112(11):1566-72. PMID: 16144993.
    View in: PubMed
  119. Mora S, Yanek LR, Moy TF, Fallin MD, Becker LC, Becker DM. Interaction of body mass index and framingham risk score in predicting incident coronary disease in families. Circulation. 2005 Apr 19; 111(15):1871-6. PMID: 15837938.
    View in: PubMed
  120. Mora S, Redberg RF, Cui Y, Whiteman MK, Flaws JA, Sharrett AR, Blumenthal RS. Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: a 20-year follow-up of the lipid research clinics prevalence study. JAMA. 2003 Sep 24; 290(12):1600-7. PMID: 14506119.
    View in: PubMed
  121. Mora S, Kershner DW, Vigilance CP, Blumenthal RS. Coronary Artery Disease in Postmenopausal Women. Curr Treat Options Cardiovasc Med. 2001 Feb; 3(1):67-79. PMID: 11139791.
    View in: PubMed
  122. Mora S, Blumenthal RS. Mild hypercholesterolemia and premature coronary artery disease. Cardiol Rev. 2001; 18:33-34.
  123. Mora S, Stafford RS, Pasternak RC. Certain cardiac risk factors predict risk factor interventions and influence communication between physicians and patients. Am J Cardiol. 2000 Oct 01; 86(7):783-5, A9. PMID: 11018202.
    View in: PubMed
  124. Nowak RA, Mora S, Diehl T, Rhoades AR, Stewart EA. Prolactin is an autocrine or paracrine growth factor for human myometrial and leiomyoma cells. Gynecol Obstet Invest. 1999; 48(2):127-32. PMID: 10461005.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Mora's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_